Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Lilly

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dale M. Edgar, Ph.D. has been appointed executive director and chief scientific leader of Eli Lilly and Co.’s discovery sleep research program. Dr. Edgar has more than 25 years of experience in the field of sleep research. He will report to David Bredt, M.D., vice president of integrated biology.

“We are delighted that Dale has decided to bring his considerable expertise to Lilly,” said Dr. Bredt. “He brings a wealth of experience in sleep research as well as innovative insights into preclinical and clinical drug discovery. We look forward to having him join the team here at Lilly, and to adding renewed emphasis to our sleep disorder research program.”

Dr. Edgar was formerly chief science and technology officer at Hypnion, Inc., a Lexington, MA-based biopharmaceutical company focused on treatments for sleep disorders. He co-founded Hypnion with three other sleep and biological rhythms experts in 2000; Lilly subsequently acquired Hypnion in January of this year. Prior to founding Hypnion, he was Associate Professor of Psychiatry & Behavioral Sciences at Stanford University, and faculty investigator at the Stanford University Sleep Disorders Research Center in California.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics